Coronavirus (2019-nCoV): Currently No Medical Countermeasures Exist
—UPDATE– February 5, 2020: See FDA Issues Emergency Use Authorization for First Coronavirus Diagnostic Panel —END UPDATE—
As the number of illnesses related to the latest coronavirus continues to rise, federal and international agencies are working to beef up their preparedness and response. This includes facilitating the development of countermeasures that include diagnostics, vaccines and therapeutics, because as of right now, no FDA-approved countermeasures exist.
FDA has stated that it is ready and willing to work with companies that are developing medical countermeasures to help expedite the regulatory process. “We have a vital mission to protect and promote public health and the FDA is closely collaborating with our domestic and international public health partners to mitigate the impact of the novel coronavirus that emerged in Wuhan, China,” said FDA Commissioner Stephen M. Hahn, M.D in an FDA news release. “We are actively leveraging the vast breadth of the FDA’s expertise and have begun employing the full range of our public health authorities to facilitate the development and availability of investigational medical products to help address this urgent public health situation.”
FDA has a page dedicated to the Novel coronavirus (2019-nCov). Companies seeking to develop medical countermeasures should review this page, as it provides specific information about how to move forward with diagnostics, vaccines and therapeutics. Companies can also submit their ideas via the link to the BARDA portal for the 2019 novel coronavirus.
Related Articles
-
The MDDT program was developed in collaboration with the National Institutes of Health’s (NIH’s) National Institute of Drug Abuse (NIDA), National Institute of Dental Craniofacial Research (NIDCR) and National Cancer Institute (NCI) as a way for the FDA to qualify…
-
“This report validates the broad applicability—and true value—of computational modeling and simulation as a critical engineering discipline. Tangible cost, quality and performance improvements are being realized by the early adopters.”
-
Leslie Trigg, CEO of Outset Medical, is the new Chair of The Medical Device Manufacturers Association (MDMA) Board of Directors.
-
On the journey to full-scale production for medical devices incorporating optics, a series of steps early in the process can make all the difference for successfully launching new products and introducing next-generation upgrades. This article discusses four considerations for a…
